Canada
· Delayed Price · Currency is CAD PharmaCielo Statistics
Total Valuation
PharmaCielo has a market cap or net worth of CAD 14.43 million. The enterprise value is 35.30 million.
| Market Cap | 14.43M |
| Enterprise Value | 35.30M |
Important Dates
The last earnings date was Wednesday, November 27, 2024.
| Earnings Date | Nov 27, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
PharmaCielo has 169.75 million shares outstanding. The number of shares has increased by 7.73% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 169.75M |
| Shares Change (YoY) | +7.73% |
| Shares Change (QoQ) | -4.55% |
| Owned by Insiders (%) | 7.07% |
| Owned by Institutions (%) | 4.74% |
| Float | 157.74M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 5.52 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -2.52 |
| EV / Sales | 13.59 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -11.44 |
Financial Position
The company has a current ratio of 0.15
| Current Ratio | 0.15 |
| Quick Ratio | 0.07 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -6.77 |
| Interest Coverage | -8.54 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -16.00% |
| Return on Capital (ROIC) | -22.55% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.11 |
| Inventory Turnover | 1.26 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -37.04% in the last 52 weeks. The beta is 2.44, so PharmaCielo's price volatility has been higher than the market average.
| Beta (5Y) | 2.44 |
| 52-Week Price Change | -37.04% |
| 50-Day Moving Average | 0.10 |
| 200-Day Moving Average | 0.15 |
| Relative Strength Index (RSI) | 42.99 |
| Average Volume (20 Days) | 192,646 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, PharmaCielo had revenue of CAD 2.60 million and -14.03 million in losses. Loss per share was -0.08.
| Revenue | 2.60M |
| Gross Profit | 31,080 |
| Operating Income | -5.93M |
| Pretax Income | -14.03M |
| Net Income | -14.03M |
| EBITDA | -6.53M |
| EBIT | -5.93M |
| Loss Per Share | -0.08 |
Balance Sheet
The company has 25,313 in cash and 20.90 million in debt, giving a net cash position of -20.87 million or -0.12 per share.
| Cash & Cash Equivalents | 25,313 |
| Total Debt | 20.90M |
| Net Cash | -20.87M |
| Net Cash Per Share | -0.12 |
| Equity (Book Value) | -7.60M |
| Book Value Per Share | -0.04 |
| Working Capital | -19.38M |
Cash Flow
In the last 12 months, operating cash flow was -3.08 million and capital expenditures -5,282, giving a free cash flow of -3.09 million.
| Operating Cash Flow | -3.08M |
| Capital Expenditures | -5,282 |
| Free Cash Flow | -3.09M |
| FCF Per Share | -0.02 |
Margins
| Gross Margin | 1.20% |
| Operating Margin | -228.48% |
| Pretax Margin | -540.35% |
| Profit Margin | n/a |
| EBITDA Margin | -251.31% |
| EBIT Margin | -228.48% |
| FCF Margin | n/a |
Dividends & Yields
PharmaCielo does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -7.73% |
| Shareholder Yield | -7.73% |
| Earnings Yield | -97.82% |
| FCF Yield | -21.39% |
Stock Splits
The last stock split was on January 18, 2019. It was a reverse split with a ratio of 0.083752.
| Last Split Date | Jan 18, 2019 |
| Split Type | Reverse |
| Split Ratio | 0.083752 |
Scores
PharmaCielo has an Altman Z-Score of -16.06. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -16.06 |
| Piotroski F-Score | n/a |